safinamide has been researched along with Disease Models, Animal in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bahn, YS; Choi, JW; Han, G; Jang, BK; Kim, HJ; Kim, S; Lee, YR; Lee, YS; Pae, AN; Park, JH; Park, KD; Shin, SJ; Yeon, SK | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Dinda, AK; Joshi, B; Reeta, KH; Sharma, U; Singh, D; Wasan, H | 1 |
| Brugnoli, A; Caccia, C; Gardoni, F; Keywood, C; Kulisevsky, J; Mellone, M; Melloni, E; Morari, M; Novello, S; Padoani, G; Pisanò, CA; Sosti, V; Vailati, S | 1 |
| Bechtold, D; Chauhdry, S; Hassoon, P; Lee, W; Malpass, K; Morsali, D; Palchaudhuri, U; Piers, T; Pocock, J; Roach, A; Smith, KJ; Snell, DM | 1 |
| Dustrude, ET; Khanna, R; Kohn, H; Park, KD; Ripsch, MS; Wang, Y; White, FA; Yang, XF | 1 |
| Caccia, C; Calabresi, M; Curatolo, L; Faravelli, L; Fariello, RG; Maestroni, S; Maj, R; Salvati, P | 1 |
| Fariello, RG; Maj, R; McArthur, RA; Pevarello, P; Salvati, P; Varasi, M | 1 |
1 review(s) available for safinamide and Disease Models, Animal
| Article | Year |
|---|---|
Safinamide: from molecular targets to a new anti-Parkinson drug.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Brain Ischemia; Disease Models, Animal; Gerbillinae; Humans; Kainic Acid; Levodopa; Mice; MPTP Poisoning; Neurons; Rats; Veratridine | 2006 |
7 other study(ies) available for safinamide and Disease Models, Animal
| Article | Year |
|---|---|
Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzene Derivatives; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Structure-Activity Relationship | 2018 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Post Stroke Safinamide Treatment Attenuates Neurological Damage by Modulating Autophagy and Apoptosis in Experimental Model of Stroke in Rats.
Topics: Alanine; Animals; Apoptosis; Autophagy; Benzylamines; Brain; Cytokines; Disease Models, Animal; Infarction, Middle Cerebral Artery; Male; Motor Activity; Neuroprotective Agents; Oxidative Stress; Rats; Rats, Sprague-Dawley; Stroke | 2021 |
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Signal Transduction | 2018 |
Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis.
Topics: Alanine; Animals; Benzylamines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Flecainide; Male; Microglia; Multiple Sclerosis; Neuroprotective Agents; Rats; Sodium Channel Blockers | 2013 |
Chimeric agents derived from the functionalized amino acid, lacosamide, and the α-aminoamide, safinamide: evaluation of their inhibitory actions on voltage-gated sodium channels, and antiseizure and antinociception activities and comparison with lacosamid
Topics: Acetamides; Alanine; Analgesics; Animals; Anticonvulsants; Benzylamines; Cells, Cultured; Cerebral Cortex; Disease Models, Animal; Female; Formaldehyde; Lacosamide; Male; Membrane Potentials; Mice; Neuralgia; Neurons; Patch-Clamp Techniques; Rats, Sprague-Dawley; Seizures; Tibial Nerve; Voltage-Gated Sodium Channel Blockers; Voltage-Gated Sodium Channels | 2015 |
Anticonvulsant activity of PNU-151774E in the amygdala kindled model of complex partial seizures.
Topics: Acetates; Alanine; Amines; Amygdala; Animals; Anticonvulsants; Behavior, Animal; Benzylamines; Carbamazepine; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Epilepsy, Complex Partial; Gabapentin; gamma-Aminobutyric Acid; Kindling, Neurologic; Lamotrigine; Male; Phenytoin; Rats; Rats, Wistar; Severity of Illness Index; Triazines | 1999 |